Express Testing-Method Specifications Control: “85% Fatty Acids GC” Does Not Imply an Additional Purity/Non‑Adulteration Warranty

1. Introduction

In Jiaherb Inc v. MTC Industries Inc (3d Cir. July 24, 2026) (nonprecedential), the Third Circuit affirmed a post–bench-trial judgment for the seller, MTC Industries, in a commercial dispute over the alleged adulteration of saw palmetto oil.

Parties and transaction. Jiaherb, a seller of dietary supplement ingredients, purchased 17,266 kg of saw palmetto oil from MTC across multiple purchase orders. The parties did not sign a single integrated agreement; instead, performance followed a recurring course: purchase order → sample/COA → Jiaherb testing → confirmation → shipment.

Core issue. Two batches later tested “possibly adulterated” by a customer’s laboratory using NMR. The dispute centered on what the contracts required: whether the purchase-order term “Saw Palmetto Oil | Fatty Acids 85% GC” required only GC confirmation of fatty acid content/profile (as MTC argued), or also an independent contractual obligation that the oil be “pure” and “unadulterated” even if other testing methods (like NMR) suggested otherwise (as Jiaherb argued).

Claims on appeal. Jiaherb appealed the rejection of (i) breach of contract, (ii) Lanham Act false advertising, and (iii) breach of the implied covenant of good faith and fair dealing—each ultimately depending on proving adulteration or contractual nonconformance.

2. Summary of the Opinion

The Third Circuit affirmed the judgment for MTC. It held that:

  • The purchase-order quality term was ambiguous, so the District Court’s interpretation was reviewed for clear error, and the appellate court found none.
  • The District Court did not abuse its discretion (or plainly err) in its key evidentiary rulings, including admitting MTC’s NMR-focused expert testimony and declining to treat Jiaherb’s unoffered Eurofins report as admitted evidence.
  • The District Court did not clearly err in finding that the batches satisfied the contractual/USP GC specifications and were not proven adulterated; thus Jiaherb’s Lanham Act and implied-covenant claims also failed.

Although designated NONPRECEDENTIAL, the opinion is a detailed application of New Jersey contract interpretation principles and federal evidentiary standards in a recurring commercial setting: specifications tied to a particular analytical method.

3. Analysis

3.1 Precedents Cited

Contract interpretation framework and standards of review

  • In re Nat'l Collegiate Student Loan Trs. 2003-1, 2004-1, 2004-2, 2005-1, 2005-2, 2005-3, 971 F.3d 433, 443 (3d Cir. 2020): Supplied the interpretive taxonomy—distinguishing “interpretation” (ascertaining meaning) from “construction” (legal effect)—and linked that distinction to the standard of review. The panel used this to decide that the dispute involved interpretation (ambiguous term), triggering clear-error review of the District Court’s meaning finding.
  • Garden State Tanning, Inc. v. Mitchell Mfg. Grp., Inc., 273 F.3d 332, 335 (3d Cir. 2001): Cited for the proposition that ambiguity shifts the inquiry to interpretive factfinding (clear-error review), whereas unambiguous language is reviewed as a matter of law.
  • Wayne Land & Min. Grp. LLC v. Del. River Basin Comm'n, 894 F.3d 509, 528 (3d Cir. 2018): Used to anchor the appellate court’s de novo role in determining whether the contractual language is ambiguous in the first instance.
  • Chubb Custom Ins. Co. v. Prudential Ins. Co. of Am., 948 A.2d 1285, 1289 (N.J. 2008): Invoked for the New Jersey articulation that competing reasonable interpretations indicate ambiguity—supporting the panel’s conclusion that neither party’s reading was facially unreasonable.

Clear-error review of factfinding and credibility

  • Berg Chilling Sys., Inc. v. Hull Corp., 369 F.3d 745, 754 (3d Cir. 2004) (quoting Kool, Mann, Coffee & Co. v. Coffey, 300 F.3d 340, 353 (3d Cir. 2002)): Provided the demanding definition of “clear error” that controlled the appeal’s posture. The panel repeatedly emphasized that where the trial court has evidentiary support and rational reasons for its findings—especially on technical expert disputes—appellate reversal is inappropriate.

Contract text must give effect to all words (anti-superfluity)

  • Wash. Const. Co. v. Spinella, 84 A.2d 617, 619 (N.J. 1951) (quoting 9 Williston on Contracts): Supplied the interpretive canon that each word should be given effect. This was decisive in rejecting Jiaherb’s attempt to read the term as requiring broader “purity” confirmation by unspecified methods; doing so would render “GC” in “85% GC” superfluous.

Bench-trial appellate review and evidentiary rulings

  • Travelers Cas. & Sur. Co. v. Ins. Co. of N. Am., 609 F.3d 143, 156-57 (3d Cir. 2010): Cited for the standard framework after a bench trial: factual findings (clear error), legal conclusions (de novo), evidentiary rulings (abuse of discretion).

Expert testimony under Rule 702; “fit”; and plain-error limits

  • United States v. Anderson, 171 F.4th 232, 236 (3d Cir. 2026): Cited for Rule 702’s core requirements—qualification plus relevance and reliability—and the centrality of methodology to reliability.
  • Elcock v. Kmart Corp., 233 F.3d 734, 741 (3d Cir. 2000): Used to define “fit” (relevance) in the expert context. The panel applied it to uphold admitting Dr. Wang’s testimony as fitting the specific dispute—whether Isura’s NMR work supported an adulteration conclusion—even if Dr. Wang was not a “botanical adulteration” specialist.
  • United States v. Kolodesh, 787 F.3d 224, 234 n.12 (3d Cir. 2015): Used to confine appellate review to plain error on objections not preserved at trial (here, the methodology critique of Dr. Wang’s testimony).

Lanham Act falsity and New Jersey implied covenant

  • Groupe SEB USA, Inc. v. Euro-Pro Operating LLC, 774 F.3d 192, 198 (3d Cir. 2014): Cited on the elements of a Lanham Act false advertising theory; the panel used it to explain why, absent proof of adulteration (the asserted falsity), the Lanham Act claim necessarily fails.
  • Sons of Thunder, Inc. v. Borden, Inc., 690 A.2d 575, 589 (N.J. 1997): Cited for New Jersey’s implied covenant standards (bad faith/dishonesty). Because Jiaherb offered no alternative “bad faith” theory beyond alleged adulteration, losing on adulteration meant losing on the implied-covenant claim.

3.2 Legal Reasoning

(a) The “new” practical rule: specifications tied to a testing method limit the contractual quality promise

The court treated the quality term—“Saw Palmetto Oil | Fatty Acids 85% GC”—as ambiguous but ultimately upheld the District Court’s finding that it meant: at least 85% fatty acids as determined by GC, not “purity” established by any other method that might later be used by a downstream customer or third-party lab.

Three strands of reasoning converged:

  1. Textual anchoring. The term expressly references GC. Under Wash. Const. Co. v. Spinella, a reading that would allow any later method to override GC would dilute or nullify the “GC” limitation.
  2. Party admissions/course of dealing evidence. The District Court relied on testimony from Jiaherb’s CEO and quality control manager acknowledging that the operative term called for GC testing and that USP compliance (as invoked in the COAs) likewise centered on GC. The Third Circuit found that evidentiary basis sufficient to defeat clear-error challenge.
  3. Allocation of proof and persuasion. By framing the dispute as “did Jiaherb prove adulteration?” and “did Jiaherb prove nonconformance with the GC-based specification?”, the court underscored that contract-liability did not arise merely because an alternate test created suspicion—especially where the product repeatedly passed the contract-referenced test.

(b) Expert evidence: the court permitted targeted methodological critique without requiring a “counter-test”

Jiaherb attacked MTC’s expert, Dr. Poguang Wang, as lacking a botanical-adulteration focus and as offering critique rather than an independent NMR analysis. The Third Circuit rejected both points:

  • Fit. The dispute was about the meaning of Isura’s NMR work and whether it supported an adulteration inference. The trial court thus properly focused on Dr. Wang’s expertise with NMR testing rather than requiring a narrower credential set.
  • No requirement to “run your own test.” Because Jiaherb bore the burden of proving adulteration, it was enough for MTC to undermine the reliability/interpretability of Jiaherb’s proof. The appellate court treated this as a straightforward application of burdens of proof: a defendant may prevail by demonstrating that plaintiff’s evidence is insufficient, not only by producing affirmative independent measurements.

(c) Evidentiary asymmetry: courts do not admit unoffered reports sua sponte

Jiaherb complained that MTC’s lab reports came in as business records while Jiaherb’s Eurofins report did not. The Third Circuit’s response was bluntly procedural: Jiaherb did not offer its report, and it did not establish an applicable hearsay exception. The court refused to impose a duty on trial judges to cure a party’s evidentiary omissions on their own initiative.

(d) Factual finding on adulteration: deferential review plus a credibility-based technical assessment

The panel emphasized that the District Court’s no-adulteration finding was supported by:

  • Multiple rounds of GC testing by both parties showing compliance with the USP fatty-acid profile and the 85% threshold;
  • Specific critiques of Isura’s NMR presentation and Jiaherb’s expert’s visual-only comparison of spectra without the underlying numeric data;
  • The District Court’s reasoned choice to credit Dr. Wang’s methodological concerns over Kababick’s interpretive approach.

Under Berg Chilling Sys., Inc. and Kool, Mann, Coffee & Co., that evidentiary support foreclosed clear-error reversal.

(e) Downstream claims (Lanham Act and implied covenant) rise or fall with proof of adulteration

The court treated adulteration as the lynchpin factual predicate. Without it, there was no “falsity” for the Lanham Act theory (per Groupe SEB USA, Inc. v. Euro-Pro Operating LLC) and no independent bad-faith conduct to support an implied-covenant claim (per Sons of Thunder, Inc. v. Borden, Inc.).

3.3 Impact

Commercial contracting for regulated/standardized ingredients

The opinion’s most significant practical takeaway is the court’s willingness—when supported by testimony and the contract’s phrasing—to treat method-referenced specifications as limiting the contractual promise. If buyers want a broader warranty (e.g., “unadulterated,” “authentic botanical identity,” “no added oils,” or “must pass NMR/PCA screen”), they should negotiate and draft it expressly rather than assuming an industry standard will be judicially implied.

Testing-method conflicts (GC vs. NMR) and litigation proof

The decision also signals that where a contract and governing monograph focus on one analytical method (here, GC), plaintiffs face an uphill climb if they rely primarily on a different method (here, NMR) without robust validation, transparent data, and an explanation tying that method to the contractual/industry acceptance for that ingredient.

Expert strategy and burdens

For future bench trials involving technical analytics, the opinion reinforces that a defendant can prevail through methodological impeachment of the plaintiff’s testing without conducting its own mirror-image testing— especially when the plaintiff bears the ultimate burden of proof on nonconformance/adulteration.

Evidence management: reports, hearsay exceptions, and preservation

The ruling underscores a recurring trial lesson: technical reports are not “in” merely because they exist or seem comparable to admitted documents. Parties must offer the exhibit and lay the foundation (e.g., business-records predicate), and must preserve objections or face plain error review.

4. Complex Concepts Simplified

  • GC (gas chromatography). A lab technique that separates and quantifies chemical components. Here, it was used to measure total fatty acids and a required profile/ratio specified by USP.
  • NMR (nuclear magnetic resonance) spectra. A technique producing spectral “peaks” that reflect chemical environments in a sample. The court credited testimony that visual comparisons of spectra without the underlying numerical dataset can be unreliable for drawing adulteration conclusions.
  • USP 37 / monograph standards. Published compendial specifications used as industry benchmarks. The opinion treated USP 37 as the governing reference for the batches, but emphasized that the relevant USP method for the contractual measure was GC.
  • COA (certificate of analysis). A document reporting test results for a batch. Jiaherb argued COAs added contractual obligations; the court noted that even if they did, they still pointed to GC-based compliance.
  • Ambiguity; interpretation vs. construction. If a term can reasonably mean two things, it is ambiguous; then a trial court’s meaning-finding is reviewed deferentially for clear error.
  • Clear error vs. abuse of discretion vs. plain error. “Clear error” is highly deferential to factfinding; “abuse of discretion” defers to evidentiary management; “plain error” is even harder to show and applies when an argument was not properly preserved.
  • Rule 702 “fit.” Expert testimony must match (“fit”) the question the court must decide; a witness need not be the most specialized possible expert if their expertise squarely addresses the methodological dispute.
  • Implied covenant of good faith and fair dealing (New Jersey). A background duty not to act in bad faith to deprive the other party of contractual benefits; it cannot substitute for proof of the factual predicate (here, adulteration) when that is the sole alleged bad-faith conduct.
  • Lanham Act false advertising. Requires, among other things, a false or misleading statement of fact in commercial advertising; here, Jiaherb identified no falsity apart from the alleged adulteration.

5. Conclusion

Jiaherb Inc v. MTC Industries Inc affirms a commercially significant interpretive approach: where a purchase order specifies a quality threshold and an explicit testing method (here, “85% … GC”), courts may treat that method as delimiting the contractual quality obligation, absent clearer language imposing broader authenticity or “no added oils” requirements.

The opinion also illustrates how, in technically complex adulteration disputes, outcomes often turn less on the existence of competing tests and more on (i) contractual drafting, (ii) the transparency and interpretability of the scientific data offered, (iii) the trial court’s credibility determinations, and (iv) disciplined evidentiary practice and preservation.